Intestine-lung Axis of Cystic Fibrosis Patients Treated With the Combination Elexacaftor/Tezacaftor/Ivacaftor
Conditions
Cystic Fibrosis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
CHU de Bordeaux - CRCM pédiatrique, Bordeaux, France
Contact: Study coordinator (Raphaël ENAUD)CHU de Grenoble Alpes CRCM pédiatrique, Grenoble, France
Contact: Study coordinator (Catherine LLerena)CHRU de Lille CRCM Pédiatrique, Lille, France
Contact: Study coordinator (Nathalie Wizla)CHU de Limoges CRCM Limousin, Limoges, France
Contact: Study coordinator (Alexandra Masson-Rouchaud)Hospices Civils de Lyon Service de pédiatrie, allergologie et mucoviscidose, Lyon, France
Contact: Study coordinator (Philippe Reix)AP-HM CRCM pédiatrique, Marseille, France
Contact: Study coordinator (Jean-Christophe Dubus)CHU de Montpellier, Montpellier, France
Contact: Study coordinator (Raphael CHIRON)CHU de Nancy, Nancy, France
Contact: Study coordinator (Aurélie Tatopoulos)CHU de Nice, Nice, France
Contact: Study coordinator (Sylvie Leroy)AP-HP CRCM Robert debré, Paris, France
Contact: Study coordinator (Michèle GERARDIN)AP-PH Hopital Cochin service de pédiatrie, Paris, France
Contact: Study coordinator (Pierre-Régis BURGEL)APHP Hopital Necker, Paris, France
Contact: Study coordinator (Isabelle Sermet Gaudelus)Fondation Ildys, Roscoff Centre Hélio Marin - Clinique "Mucoviscidose", Roscoff, France
Contact: Study coordinator (Sophie RAMEL)CHU de Rouen, Rouen, France
Contact: Study coordinator (Hélène Morisse Pradier)CHU de Toulouse, Toulouse, France
Contact: Study coordinator (Marie Mittaine)
Study leads
Raphaël Enaud, MDPhD
Principal Investigator
University Hospital, Bordeaux